The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance

Blood Science · Published 2026-02-18 · DOI 10.1097/bs9.0000000000000270

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1097/bs9.0000000000000270

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• ITP, easy as EBV: a rare case of severe immune thrombocytopenic purpura secondary to Epstein-Barr virus · Blood Science · 2026 · Same journal
• CD7 CAR-T therapy: current developments, improvements, and dilemmas · Blood Science · 2025 · Same journal
• Novel NUP98:TNRC18 fusion transcript in acute myeloid leukemia: a case report and literature review · Blood Science · 2025 · Same journal
• Single-cell transcriptomic dissection of two waves of endothelial-hematopoietic transition in a murine yolk sac · Blood Science · 2025 · Same journal
• Diagnostic value of mNGS for CNSIs in hematopoietic stem cell transplant patients · Blood Science · 2025 · Same journal
• A promising leap in treating large granular lymphocytic leukemia: reflections on a Multicenter Phase II Study of thalidomide-based therapy · Blood Science · 2025 · Same journal
• Application value and challenges associated with plasma cell-free DNA metagenomic sequencing technology in the diagnosis of infections in patients with hematological disorders · Blood Science · 2026 · Same journal
• Development and validation of nomograms for survival prediction in Fanconi anemia · Blood Science · 2025 · Same journal
• The groundbreaking discovery of peripheral immune tolerance: identifying Treg cells and the FOXP3 gene, and their therapeutic potential · Blood Science · 2025 · Same journal
• Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy · Blood Science · 2026 · Same journal